États-Unis · Plateformes & données · Stocktwits

Sellas To Present SLS009 Data At American Society of Hematology – Initial Results Of Therapy In Newly Diagnosed AML Patients Expected In Q4

Publié par Stocktwits · États-Unis il y a 9 h

Sellas Life Sciences (SLS) was in the spotlight on Wednesday after the biotech firm said it will present Phase 2 results for its experimental blood cancer treatment SLS009 at the…

Lire l'article complet sur Stocktwits Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (stocktwits.com)

Sellas To Present SLS009 Data At American Society of Hematology – Initial Results Of Therapy In Newly Diagnosed AML Patients Expected In Q4

À lire aussi

Avis (CAR) Q3 2026 Earnings Call Transcript

Hospital stocks rally while drugmakers brace for scrutiny. Here’s what the Democratic wave means for healthcare.

10-year Treasury yield slides as traders mull over Democrats' midterm victories, oil prices drop

Curtiss-Wright stock hits 52-week low at 453.32 USD

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

Gübre Fabrikaları Reports Share Buyback, Holdings Reach 1.1164%

Sellas To Present SLS009 Data At American Society of Hematology – Initial Results Of Therapy In Newly Diagnosed AML Patients Expected In Q4

Partager

À lire aussi

Avis (CAR) Q3 2026 Earnings Call Transcript

Hospital stocks rally while drugmakers brace for scrutiny. Here’s what the Democratic wave means for healthcare.

10-year Treasury yield slides as traders mull over Democrats' midterm victories, oil prices drop

Curtiss-Wright stock hits 52-week low at 453.32 USD

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

Gübre Fabrikaları Reports Share Buyback, Holdings Reach 1.1164%